0
Communications to the Editor |

Inhaled β-Adrenoreceptor Agonists and Left Ventricular Systolic Function FREE TO VIEW

Stephanie Noppe; Adel Aminian; Liliane Kayegeshe; Roger Hallemans; Bernard Hanson
Author and Funding Information

Hôpitaux Iris Sud Brussels, Belgium

Correspondence to: Bernard Hanson, MD, Hôpitaux Iris Sud (HIS), 142 Rue Marconi, Brussels B 1190, Belgium; e-mail: bernardhanson@swing.be



Chest. 2004;125(3):1174. doi:10.1378/chest.125.3.1174
Text Size: A A A
Published online

To the Editor:

We read with interest the article in CHEST by Au et al (June 2003)1 on the risk of inhaled β-adrenoreceptor agonists in patients with left ventricular systolic dysfunction.

However, we were astonished not to see tobacco consumption among the recorded risk factors for death or degradation. Tobacco use remains the most preventable cause of death and disability in the United States.2

Far and away the most important cause of lung cancer is exposure to tobacco smoke through active or passive smoking.3 It also is a leading cause of COPD. Tobacco smoking also has been involved in terms of the rate of cardiac death.4 In 2000, Envangelista et al5 demonstrated, using a retrospective analysis of Veterans Affairs hospital records, that noncompliance with smoking restriction was a main risk factor for multiple hospital readmissions of patients with heart failure.

We would urge the authors of any study dealing with lung-related or heart-related morbidity or mortality to include tobacco usage as part of the variables assessed.

Au, DH, Udris, EM, Fan, VS, et al (2003) Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoreceptor agonists among patients with known left ventricular systolic dysfunction.Chest123,1964-1969. [CrossRef] [PubMed]
 
Batra, V, Patkar, A, Weibel, S, et al Public health implications of voters’ attitudes regarding statewide tobacco policy.Chest2002;122,295-298. [CrossRef] [PubMed]
 
Alberg, AJ, Samet, JM Epidemiology of lung cancer.Chest2003;123(suppl),21S-49S
 
Fichtenberg, CM, Glantz, SA Association of the California tobacco control program with declines in cigarette consumption and mortality from heart disease,N Engl J Med2000;343,1772-1777. [CrossRef] [PubMed]
 
Evangelista, LS, Doering, LV, Dracup, K Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans.Am J Cardiol2000;86,1339-1342. [CrossRef] [PubMed]
 

Figures

Tables

References

Au, DH, Udris, EM, Fan, VS, et al (2003) Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoreceptor agonists among patients with known left ventricular systolic dysfunction.Chest123,1964-1969. [CrossRef] [PubMed]
 
Batra, V, Patkar, A, Weibel, S, et al Public health implications of voters’ attitudes regarding statewide tobacco policy.Chest2002;122,295-298. [CrossRef] [PubMed]
 
Alberg, AJ, Samet, JM Epidemiology of lung cancer.Chest2003;123(suppl),21S-49S
 
Fichtenberg, CM, Glantz, SA Association of the California tobacco control program with declines in cigarette consumption and mortality from heart disease,N Engl J Med2000;343,1772-1777. [CrossRef] [PubMed]
 
Evangelista, LS, Doering, LV, Dracup, K Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans.Am J Cardiol2000;86,1339-1342. [CrossRef] [PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543